1. Systemic administration of low-dose naltrexone increases bone mass due to blockade of opioid growth factor receptor signaling in mice osteoblasts
    Kenjiro Tanaka et al, 2019, Life Sciences CrossRef
  2. The Safety and Efficacy of Low‐Dose Naltrexone in the Management of Chronic Pain and Inflammation in Multiple Sclerosis, Fibromyalgia, Crohn's Disease, and Other Chronic Pain Disorders
    Denise K. Patten et al, 2018, Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy CrossRef
  3. Preclinical and clinical studies into the bioactivity of low-dose naltrexone (LDN) for oncotherapy
    Na Qu et al, 2021, International Immunopharmacology CrossRef
  4. Management von EDS
    Karina Sturm et al, 2022, Ratgeber Ehlers-Danlos-Syndrome CrossRef
  5. Low Doses Naltrexone: The Potential Benefit Effects for its Use in Patients with Cancer
    Ricardo David Couto et al, 2021, Current Drug Research Reviews CrossRef
  6. Endogenous opiates and behavior: 2017
    Richard J. Bodnar, 2020, Peptides CrossRef
  7. Bioresponsive nanostructured systems for sustained naltrexone release and treatment of alcohol use disorder: Development and biological evaluation
    Rogério A. Santos et al, 2020, International Journal of Pharmaceutics CrossRef
  8. Immunometabolic Modulatory Role of Naltrexone in BV-2 Microglia Cells
    Natalia Kučić et al, 2021, International Journal of Molecular Sciences CrossRef
  9. Survey of Lifestyle, Past Medical History and Complementary and Alternative Medicine Use Among Adult Patients Participating in the National Cancer Institute's Exceptional Responders Initiative
    Oluwadamilola Olaku et al, 2022, Translational Oncology CrossRef
  10. Functional modulation on macrophage by low dose naltrexone (LDN)
    Zhe Yi et al, 2016, International Immunopharmacology CrossRef
  11. Low-Dose Naltrexone as an Adjuvant in Combined Anticancer Therapy
    Marianna Ciwun et al, 2024, Cancers CrossRef
  12. Investigation into the restoration of TRPM3 ion channel activity in post-COVID-19 condition: a potential pharmacotherapeutic target
    Etianne Martini Sasso et al, 2024, Frontiers in Immunology CrossRef
  13. Naltrexone’s Impact on Cancer Progression and Mortality: A Systematic Review of Studies in Humans, Animal Models, and Cell Cultures
    Karina Liubchenko et al, 2021, Advances in Therapy CrossRef
  14. Is immunity in cancer the key to improving clinical outcome?: Report on the International Symposium on Immunotherapy, The Royal Society, London, UK, 12–13 May 2017
    Peter L. Stern, 2017, Therapeutic Advances in Vaccines CrossRef
  15. Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy
    Zijian Li et al, 2018, International Immunopharmacology CrossRef
  16. Naltrexone Inhibits IL-6 and TNFα Production in Human Immune Cell Subsets following Stimulation with Ligands for Intracellular Toll-Like Receptors
    Rachel Cant et al, 2017, Frontiers in Immunology CrossRef
  17. Naltrexone at low doses (LDN) and its relevance to cancer therapy
    Wai M. Liu et al, 2022, Expert Review of Anticancer Therapy CrossRef
  18. Antagonists of the Mu-Opioid Receptor in the Cancer Patient: Fact or Fiction?
    Amparo Belltall et al, 2022, Current Oncology Reports CrossRef
  19. The role of immune modulation and anti‑inflammatory agents in the management of prostate cancer: A case report of six patients
    Angus Dalgleish et al, 2022, Oncology Letters CrossRef
  20. Cancer Pain
    Jonathan Silverman et al, 2019, Academic Pain Medicine CrossRef
  21. Effects of perioperative low-dose naloxone on the immune system in patients undergoing laparoscopic-assisted total gastrectomy: a randomized controlled trial
    Xiangzhen Min et al, 2024, BMC Anesthesiology CrossRef
  22. Low-dose naltrexone as a treatment for chronic fatigue syndrome
    Monica Jane Bolton et al, 2020, BMJ Case Reports CrossRef
  23. Combination of cannabidiol with low‑dose naltrexone increases the anticancer action of chemotherapy in vitro and in vivo
    Wai Liu et al, 2022, Oncology Reports CrossRef